'BioBusiness Network delivered on all counts: a senior audience, informative presentations and an informal atmosphere for successful partnering'
Paul Higham, Director of Commercial Development, Ark Therapeutics

BioBusiness 2008 yet again confirmed this leading event’s status as the most senior-level and exclusive conference of its type. With over 230 biotech CEOs and heads of BD&L from leading pharma organisations coming together to network and gain insight from leading industry presentations, BioBusiness 2008 attendees are now confident they’re one step closer to their next big deal with a ‘partner of choice’.

If you benefited from the networking and unique presentations at BioBusiness 2008, you’ll be keen to book you place at our next event, BioBusiness Network, as soon as possible. If you missed out, this is your chance to really make a difference to your networking agenda and benefit from new features such as our ‘partnering skills workshop’, ‘emerging markets focus’, ‘innovation review’ and therapeutic-focused roundtables. Click here to go straight to the BioBusiness Network website.

Delegates benefited from intimate, high-level networking	The Networking Dinner at the Four Seasons Hotel was a huge success

The CNS focus day gave critical insight from leaders including Pfizer, Biogen Idec, Wyeth, BTG, Chroma and Pharmacopeia

Book now for BioBusiness Network 2008!

Top rated BioBusiness 2008 Speakers included:

• Kate Burt, Director Transactions, GSK
• Jane Devereux, Senior Director Corporate Licensing, Merck & Co
• Klaus Schollmeier, CEO, Santhera Pharmaceuticals
• Joern-Peter Halle, Head of Early Stage Licensing, Merck Serono
• Jules Musing, Head of Business Development, J&J
• Vincent Mutel, CEO, Addex
• Gad Bitton, Global Alliance Director, Roche
• Andy Davis, Director Business Development, Amgen Europe
• Eugen Leo, Medical Leader, J&J
• Bharatt Chowrira, Vice President, Sirna Therapeutics
• Ian Nicholson, CEO, Choma Therapeutics

37 Industry Case Studies Presented in 2008 Including:

• Denise Good, Executive Transaction Director, AstraZeneca and Janette Dean, Senior Director Business Development at BMS, who gave a fascinating insight into how they put together their successful risk-sharing collaboration
• Geoff Swire of Genzyme and Gary Bridger of AnorMED, whose frank and open insight into Genzyme’s recent ‘unsolicited’ takeover of AnorMED gave delegates a unique view into the first deal of this kind.
• Bob Nelson, Senior Research Fellow at Pfizer, who gave thorough insight into current work in CNS and the impact it will have on the market.
• Uwe Gudat, Principal Medical Scientific Expert, Novartis, who gave an energetic and thorough presentation on metabolic disease, including offering invaluable insight to biotechs on what medical experts expect to see when assessing deals internally
• Adrian Carter of Boehringer Ingelheim and Eva-Lotta Allen, CBO of Ablynx, whose account of finding a cultural fit between organisations cast new light on deal negotiation and alliance management
• Philip Oliver, Associate Director, Global External R&D, Eli Lilly, who gave an account of some of the work currently undertaken as part of their Chorus project, which is accelerating research to proof of concept at unprecedented rates.
• Nick Adams, Director of Business Development, Antisoma and Alan Warrander, industry expert, who gave an amusing and revealing insight into the negotiation process

Speaker Opportunities:

If you are interested in Speaking at BioBusiness Network, please contact Frances Parker at frances.parker@wbr.co.uk or call on+44 207 368 9464

CD Rom

To purchase the BioBusiness 2008 CD ROM (all presentations included) /Audio presentation(s), go to www.shopwbr.com or call us on +44 (0) 20 7368 9400.

Sponsorship Opportunities

To learn more about sponsorship opportunities at BioBusiness Network please contact Frances Parker at frances.parker@wbr.co.uk or call on+44 207 368 9464